UnratedDrug recall · FDA · Published April 12, 2022
Preferred Pharmaceuticals recalls Losartan 50mg tablets due to unsafe impurity levels
Preferred Pharmaceuticals recalls 30-count Losartan Potassium 50mg tablets (Lupin Pharmaceuticals) with high azido impurity levels. Consumers should check lot numbers on packaging for affected batches.
“Preferred Pharmaceuticals recalls Losartan 50mg tablets due to unsafe impurity levels.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34969-preferred-pharmaceuticals-recalls-losartan-50mg-tablets-due-to-unsafe-impurity. Based on FDA recall #D-0789-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0789-2022%22&limit=1).
The FDA announced on April 12, 2022, that Preferred Pharmaceuticals, Inc. voluntarily recalled Losartan Potassium Tab. USP 50mg due to azido impurity levels exceeding acceptable limits. The recall involves specific lots distributed nationwide to California, Indiana, and Florida.
How to tell if you have it
Brand: Preferred Pharmaceuticals
Product: Losartan Potassium Tab. USP 50mg
Manufacturer: Lupin Pharmaceuticals, Inc., Preferred Pharmaceuticals, Inc.
Lot codes: E1321O, E2521H, E2621F
Expiration date: 5/31/2023
Package sizes: 30 tablets, 90 tablets
Distribution: Nationwide within the U.S. to CA, IN and FL
The hazard
The recall was initiated because current good manufacturing practice (CGMP) deviations resulted in azido impurity levels observed to be above acceptable limits. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Preferred Pharmaceuticals, Inc. has 31 other recalls on record since August 15, 2018. Other recent recalls of similar products include Geri-Care Eye Drops Recalled for Sterility Risk (March 25, 2026) and Preferred Pharma Recalls Ondansetron ODT Due to Defective Seals (November 17, 2025). Additional related actions noted in records are Preferred Pharma Recalls Clindamycin Capsules Due to cGMP Deviations (April 18, 2025), Amneal traMADol 50mg Tablets Recall: NDSRI Impurity Risk (March 19, 2026), Lupin Ganirelix Acetate Injection Recall: Impurity Risk (November 13, 2025), and Ajanta Pharma Recalls Duloxetine Capsules Due to Nitrosamine Impurity Risk (April 29, 2026).
How to tell if you have this one
Check the packaging for lot numbers E1321O, E2521H, or E2621F that expire May 31, 2023. The product is sold in 30-count packages.
Brand
Preferred Pharmaceuticals
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Lot Number
Look for lot numbers E1321O, E2521H, or E2621F on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide; the notice names 3 states.
Named in the notice
Covered by “nationwide”
Not listed
FDA distribution: “Nationwide within the U.S to CA, IN and FL.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Named in the notice: California, Florida, Indiana.
Recall timeline
FDA terminated this recall 5 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0789-2022 (April 12, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0789-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.